Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Svea Hüning

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Der Hautarzt; Zeitschrift Fur Dermatologie, Venerologie, Und Verwandte Gebiete|November 14, 2019
[Supportive therapy and management of side effects in dermato-oncology]Laura von Dücker, Svea Hüning, Katharina Kähler, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|May 22, 2025
Supportive pain therapy in dermatologyMarkus Werner, Waltraud Stromer, Svea Hüning, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|September 30, 2025
Brentuximab vedotin and radiotherapy for CD30-positive cutaneous T-cell lymphoma - a retrospective multicenter analysisPatrick Schummer, Caroline Glatzel, Philipp Schrüfer, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|April 20, 2026
Development and validation of the Essen Melanoma Quality of Life Inventory (EMQoLI)Venja Musche, Theresa Schadendorf, Adam Schweda, et al.
European Journal of Cancer (Oxford, England : 1990)|October 10, 2024
Short- and long-term immunosuppressive effects of melanoma influence the prognostic value of the sentinel lymph node statusViola K DeTemple, Cathrin Ritter, Nalini Srinivas, et al.
Cancers|June 2, 2021
Factors Influencing the Adjuvant Therapy Decision: Results of a Real-World Multicenter Data Analysis of 904 Melanoma PatientsGeorg Lodde, Andrea Forschner, Jessica Hassel, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|November 26, 2022
Immune checkpoint inhibition and targeted therapy for melanoma: A patient-oriented cross-sectional comparative multicentre studyAlexander Thiem, Pegah Mashhadiakbar, Christiane Cussigh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 3, 2025
Long-Term Follow-Up of Real-World Adjuvant Anti-PD-1 Checkpoint Inhibition and Targeted Therapy in Patients With Stage III MelanomaGeorg C Lodde, Jessica C Hassel, Imke von Wasielewski, et al.
Journal of Clinical Medicine|May 16, 2020
Treatment Motivations and Expectations in Patients with Actinic Keratosis: A German-Wide Multicenter, Cross-Sectional TrialTheresa Steeb, Anja Wessely, Dagmar von Bubnoff, et al.
European Journal of Cancer (Oxford, England : 1990)|July 24, 2023
Adjuvant treatment and outcome of stage III melanoma patients: Results of a multicenter real-world German Dermatologic Cooperative Oncology Group (DeCOG) studyGeorg C Lodde, Jessica Hassel, Lena M Wulfken, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Der Hautarzt; Zeitschrift Fur Dermatologie, Venerologie, Und Verwandte Gebiete|November 14, 2019
[Supportive therapy and management of side effects in dermato-oncology]Laura von Dücker, Svea Hüning, Katharina Kähler, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|May 22, 2025
Supportive pain therapy in dermatologyMarkus Werner, Waltraud Stromer, Svea Hüning, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|September 30, 2025
Brentuximab vedotin and radiotherapy for CD30-positive cutaneous T-cell lymphoma - a retrospective multicenter analysisPatrick Schummer, Caroline Glatzel, Philipp Schrüfer, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|April 20, 2026
Development and validation of the Essen Melanoma Quality of Life Inventory (EMQoLI)Venja Musche, Theresa Schadendorf, Adam Schweda, et al.
European Journal of Cancer (Oxford, England : 1990)|October 10, 2024
Short- and long-term immunosuppressive effects of melanoma influence the prognostic value of the sentinel lymph node statusViola K DeTemple, Cathrin Ritter, Nalini Srinivas, et al.
Cancers|June 2, 2021
Factors Influencing the Adjuvant Therapy Decision: Results of a Real-World Multicenter Data Analysis of 904 Melanoma PatientsGeorg Lodde, Andrea Forschner, Jessica Hassel, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|November 26, 2022
Immune checkpoint inhibition and targeted therapy for melanoma: A patient-oriented cross-sectional comparative multicentre studyAlexander Thiem, Pegah Mashhadiakbar, Christiane Cussigh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 3, 2025
Long-Term Follow-Up of Real-World Adjuvant Anti-PD-1 Checkpoint Inhibition and Targeted Therapy in Patients With Stage III MelanomaGeorg C Lodde, Jessica C Hassel, Imke von Wasielewski, et al.
Journal of Clinical Medicine|May 16, 2020
Treatment Motivations and Expectations in Patients with Actinic Keratosis: A German-Wide Multicenter, Cross-Sectional TrialTheresa Steeb, Anja Wessely, Dagmar von Bubnoff, et al.
European Journal of Cancer (Oxford, England : 1990)|July 24, 2023
Adjuvant treatment and outcome of stage III melanoma patients: Results of a multicenter real-world German Dermatologic Cooperative Oncology Group (DeCOG) studyGeorg C Lodde, Jessica Hassel, Lena M Wulfken, et al.
Pageof 2